Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1

Conditions

Intestinal Diseases 5Constipation 5Pain 3Neoplasms 2Ovarian Neoplasms 1Opioid-Induced Constipation 1Fallopian Tube Neoplasms 1Cancer Pain 1

Interventions

Morphine 11Oxycodone 8Fentanyl 6nabiximols 5Methadone 4Hydromorphone 4Acetaminophen 3Transcutaneous Electric Nerve Stimulation 2Tapentadol 2Naloxone 2Lidocaine 2Buprenorphine 2Acupuncture Therapy 2tanezumab 1resiniferatoxin 1oxycodone naloxone combination 1fulranumab 1cannabichromene 1alvimopan 1Water 1Ultracet 1Transcranial Direct Current Stimulation 1Tramadol 1Therapeutic Touch 1Telemedicine 1Tablets 1Surveys and Questionnaires 1Sugars 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cancer Pain × alvimopan × Clear all
NCT00101998 2017-08-30

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
233 enrolled
Other

Cancer Pain, Constipation, Intestinal Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡